BioCardia Has Been Granted U.S. Patent Number 12,036,371 Titled "Method of accessing the left atrium with a multi-directional steerable catheter"
https://ppubs.uspto.gov/pubwebapp/external.html?q=(12036371).pn
https://ppubs.uspto.gov/pubwebapp/external.html?q=(12036371).pn
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/20/2021 | $9.00 | Buy | HC Wainwright & Co. |
BioCardia, Inc. (NASDAQ:BCDA), a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Unites States Patent Office has granted Patent No: 12,036,371 titled "Method of Accessing the Left Atrium with a Multi-Directional Steerable Catheter," with a patent term that will expire in 2035. The present invention relates to medical methods for transseptal access to the heart using steerable introducers based on the Company's Morph DNA technology. This additional patent protection for BioCardia's current and future products in this important existing market enhances shareholder value. Procedures that leverage
https://ppubs.uspto.gov/pubwebapp/external.html?q=(12036371).pn
CellProthera's clinical results from the Phase I/IIb EXCELLENT Trial, which studied the feasibility of transendocardial injection of ProtheraCytes for acute myocardial infarction when delivered in combination with the standard of care, suggested an effective solution for preventing heart failure progression in the patients at high risk following a heart attack.
SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2024 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. Recent Business Highlights BCDA-01: CardiAMP® autologous cell therapy in ischemic heart failure of re
SUNNYVALE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2024 by conference call on Tuesday, August 13, 2024 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10191562/fd3d36338a. Please note that registered participants will receive their dial-in number upon registration. For those who have not
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2024 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. First Quarter 2024 Highlights CardiAMP™ autologous cell therapy for patients with ischemic heart failure obser
4 - BioCardia, Inc. (0000925741) (Issuer)
4 - BioCardia, Inc. (0000925741) (Issuer)
4 - BioCardia, Inc. (0000925741) (Issuer)
HC Wainwright & Co. initiated coverage of BioCardia with a rating of Buy and set a new price target of $9.00
Dawson James downgraded BioCardia from Buy to Neutral
4 - BioCardia, Inc. (0000925741) (Issuer)
4 - BioCardia, Inc. (0000925741) (Issuer)
4 - BioCardia, Inc. (0000925741) (Issuer)
8-K - BioCardia, Inc. (0000925741) (Filer)
8-K - BioCardia, Inc. (0000925741) (Filer)
8-K - BioCardia, Inc. (0000925741) (Filer)
SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company has regained full compliance with the Nasdaq Capital Market's Listing Requirements as required by the Hearing Panel's (the "Panel") decision on May 13, 2024. On September 17, 2024, BioCardia received notice from Nasdaq confirming that the Company has demonstrated compliance with Listing Rule 5550(b)(1) (the "Equity Rule") of The Nasdaq Stock Market. Accordingly, the Panel has determined to continue the listing of the Company's securities on the Nasdaq Stock
SUNNYVALE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the closing of its upsized public offering with participation from management and directors, institutional investors, and certain existing investors of the Company for the purchase and sale of 2,400,000 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,400,000 shares of common stock at a combined offering price of $3.00 per share and accompanying warrant, priced at-the-market under Nasdaq rules. The company received aggregate gr
SUNNYVALE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the pricing of its upsized public offering with participation from management and directors, institutional investors, and certain existing investors of the Company for the purchase and sale of 2,400,000 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,400,000 shares of common stock at a combined offering price of $3.00 per share and accompanying warrant, priced at-the-market under Nasdaq rules. The company expects to receive agg
SC 13G - BioCardia, Inc. (0000925741) (Subject)
SC 13D/A - BioCardia, Inc. (0000925741) (Subject)
SC 13D/A - BioCardia, Inc. (0000925741) (Subject)